ABOS · Program file
sabirnetug
Acumen Pharmaceuticals, Inc. (ABOS)
When did Acumen Pharmaceuticals, Inc. say sabirnetug results would come?
On , Acumen Pharmaceuticals, Inc. wrote in its SEC Form 8-K: “ALTITUDE-AD topline results expected in late 2026, inclusive of efficacy, safety and biomarker data” (Source)
Days left in the window the company stated: 73 · company’s wording: “late 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- sabirnetug
- Other names in filings
- ACU193 · ALTITUDE-AD
- Indication in the filing
- Early AD
- Trials named in the same filing
- None listed
- Latest timing wording
- “ALTITUDE-AD topline results expected in late 2026, inclusive of efficacy, safety and biomarker data”
- Source
- 8-K · filed · SEC accepted · accession 0001628280-26-062137 · SEC original
- Last checked
Program ABOS-sabirnetug.